The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
CINV Existing and Pipeline Drugs-Global Market Insights and Sales Trends 2024
Synopsis
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global CINV Existing and Pipeline Drugs market size is expected to reach US$ 1954.9 million by 2029, growing at a CAGR of 3.2% from 2023 to 2029. The market is mainly driven by the significant applications of CINV Existing and Pipeline Drugs in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics and Hospital Pharmacies, are propelling CINV Existing and Pipeline Drugs market. Aloxi, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Zofran Generic segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for CINV Existing and Pipeline Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global CINV Existing and Pipeline Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global CINV Existing and Pipeline Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, CINV Existing and Pipeline Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of CINV Existing and Pipeline Drugs covered in this report include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and Tesaro, etc.
The global CINV Existing and Pipeline Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Global CINV Existing and Pipeline Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global CINV Existing and Pipeline Drugs market, Segment by Type:
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Global CINV Existing and Pipeline Drugs market, by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of CINV Existing and Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Nausea and vomiting are the two most common side effects associated with cancer chemotherapy, and are referred to as chemotherapy induced nausea and vomiting (CINV).
The global CINV Existing and Pipeline Drugs market size is expected to reach US$ 1954.9 million by 2029, growing at a CAGR of 3.2% from 2023 to 2029. The market is mainly driven by the significant applications of CINV Existing and Pipeline Drugs in various end use industries. The expanding demands from the Hospitals, Specialty Clinics, Diagnostic Centers Therapeutics and Hospital Pharmacies, are propelling CINV Existing and Pipeline Drugs market. Aloxi, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Zofran Generic segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for CINV Existing and Pipeline Drugs, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global CINV Existing and Pipeline Drugs market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global CINV Existing and Pipeline Drugs market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, CINV Existing and Pipeline Drugs sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of CINV Existing and Pipeline Drugs covered in this report include GlaxoSmithKline, Helsinn, Heron Therapeutics, Merck and Tesaro, etc.
The global CINV Existing and Pipeline Drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Helsinn
Heron Therapeutics
Merck
Tesaro
Global CINV Existing and Pipeline Drugs market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global CINV Existing and Pipeline Drugs market, Segment by Type:
Aloxi
Zofran Generic
Kytril Generic
Emend
Akynzeo
SUSTOL
Rolapitant
Global CINV Existing and Pipeline Drugs market, by Application
Hospitals
Specialty Clinics
Diagnostic Centers Therapeutics
Hospital Pharmacies
Drugstores
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of CINV Existing and Pipeline Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of CINV Existing and Pipeline Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 CINV Existing and Pipeline Drugs Market Overview
1.1 CINV Existing and Pipeline Drugs Product Overview
1.2 CINV Existing and Pipeline Drugs Market Segment by Type
1.2.1 Aloxi
1.2.2 Zofran Generic
1.2.3 Kytril Generic
1.2.4 Emend
1.2.5 Akynzeo
1.2.6 SUSTOL
1.2.7 Rolapitant
1.3 Global CINV Existing and Pipeline Drugs Market Size by Type
1.3.1 Global CINV Existing and Pipeline Drugs Market Size Overview by Type (2018-2029)
1.3.2 Global CINV Existing and Pipeline Drugs Historic Market Size Review by Type (2018-2023)
1.3.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America CINV Existing and Pipeline Drugs Sales Breakdown by Type (2018-2023)
1.4.2 Europe CINV Existing and Pipeline Drugs Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Breakdown by Type (2018-2023)
1.4.4 Latin America CINV Existing and Pipeline Drugs Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa CINV Existing and Pipeline Drugs Sales Breakdown by Type (2018-2023)
2 Global CINV Existing and Pipeline Drugs Market Competition by Company
2.1 Global Top Players by CINV Existing and Pipeline Drugs Sales (2018-2023)
2.2 Global Top Players by CINV Existing and Pipeline Drugs Revenue (2018-2023)
2.3 Global Top Players by CINV Existing and Pipeline Drugs Price (2018-2023)
2.4 Global Top Manufacturers CINV Existing and Pipeline Drugs Manufacturing Base Distribution, Sales Area, Product Type
2.5 CINV Existing and Pipeline Drugs Market Competitive Situation and Trends
2.5.1 CINV Existing and Pipeline Drugs Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by CINV Existing and Pipeline Drugs Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in CINV Existing and Pipeline Drugs as of 2022)
2.7 Date of Key Manufacturers Enter into CINV Existing and Pipeline Drugs Market
2.8 Key Manufacturers CINV Existing and Pipeline Drugs Product Offered
2.9 Mergers & Acquisitions, Expansion
3 CINV Existing and Pipeline Drugs Status and Outlook by Region
3.1 Global CINV Existing and Pipeline Drugs Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global CINV Existing and Pipeline Drugs Historic Market Size by Region
3.2.1 Global CINV Existing and Pipeline Drugs Sales in Volume by Region (2018-2023)
3.2.2 Global CINV Existing and Pipeline Drugs Sales in Value by Region (2018-2023)
3.2.3 Global CINV Existing and Pipeline Drugs Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Region
3.3.1 Global CINV Existing and Pipeline Drugs Sales in Volume by Region (2024-2029)
3.3.2 Global CINV Existing and Pipeline Drugs Sales in Value by Region (2024-2029)
3.3.3 Global CINV Existing and Pipeline Drugs Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global CINV Existing and Pipeline Drugs by Application
4.1 CINV Existing and Pipeline Drugs Market Segment by Application
4.1.1 Hospitals
4.1.2 Specialty Clinics
4.1.3 Diagnostic Centers Therapeutics
4.1.4 Hospital Pharmacies
4.1.5 Drugstores
4.2 Global CINV Existing and Pipeline Drugs Market Size by Application
4.2.1 Global CINV Existing and Pipeline Drugs Market Size Overview by Application (2018-2029)
4.2.2 Global CINV Existing and Pipeline Drugs Historic Market Size Review by Application (2018-2023)
4.2.3 Global CINV Existing and Pipeline Drugs Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America CINV Existing and Pipeline Drugs Sales Breakdown by Application (2018-2023)
4.3.2 Europe CINV Existing and Pipeline Drugs Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales Breakdown by Application (2018-2023)
4.3.4 Latin America CINV Existing and Pipeline Drugs Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa CINV Existing and Pipeline Drugs Sales Breakdown by Application (2018-2023)
5 North America CINV Existing and Pipeline Drugs by Country
5.1 North America CINV Existing and Pipeline Drugs Historic Market Size by Country
5.1.1 North America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America CINV Existing and Pipeline Drugs Sales in Volume by Country (2018-2023)
5.1.3 North America CINV Existing and Pipeline Drugs Sales in Value by Country (2018-2023)
5.2 North America CINV Existing and Pipeline Drugs Forecasted Market Size by Country
5.2.1 North America CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2029)
5.2.2 North America CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2029)
6 Europe CINV Existing and Pipeline Drugs by Country
6.1 Europe CINV Existing and Pipeline Drugs Historic Market Size by Country
6.1.1 Europe CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe CINV Existing and Pipeline Drugs Sales in Volume by Country (2018-2023)
6.1.3 Europe CINV Existing and Pipeline Drugs Sales in Value by Country (2018-2023)
6.2 Europe CINV Existing and Pipeline Drugs Forecasted Market Size by Country
6.2.1 Europe CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2029)
6.2.2 Europe CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2029)
7 Asia-Pacific CINV Existing and Pipeline Drugs by Region
7.1 Asia-Pacific CINV Existing and Pipeline Drugs Historic Market Size by Region
7.1.1 Asia-Pacific CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Value by Region (2018-2023)
7.2 Asia-Pacific CINV Existing and Pipeline Drugs Forecasted Market Size by Region
7.2.1 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific CINV Existing and Pipeline Drugs Sales in Value by Region (2024-2029)
8 Latin America CINV Existing and Pipeline Drugs by Country
8.1 Latin America CINV Existing and Pipeline Drugs Historic Market Size by Country
8.1.1 Latin America CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America CINV Existing and Pipeline Drugs Sales in Volume by Country (2018-2023)
8.1.3 Latin America CINV Existing and Pipeline Drugs Sales in Value by Country (2018-2023)
8.2 Latin America CINV Existing and Pipeline Drugs Forecasted Market Size by Country
8.2.1 Latin America CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2029)
8.2.2 Latin America CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2029)
9 Middle East and Africa CINV Existing and Pipeline Drugs by Country
9.1 Middle East and Africa CINV Existing and Pipeline Drugs Historic Market Size by Country
9.1.1 Middle East and Africa CINV Existing and Pipeline Drugs Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Value by Country (2018-2023)
9.2 Middle East and Africa CINV Existing and Pipeline Drugs Forecasted Market Size by Country
9.2.1 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa CINV Existing and Pipeline Drugs Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GlaxoSmithKline
10.1.1 GlaxoSmithKline Company Information
10.1.2 GlaxoSmithKline Introduction and Business Overview
10.1.3 GlaxoSmithKline CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
10.1.4 GlaxoSmithKline CINV Existing and Pipeline Drugs Products Offered
10.1.5 GlaxoSmithKline Recent Development
10.2 Helsinn
10.2.1 Helsinn Company Information
10.2.2 Helsinn Introduction and Business Overview
10.2.3 Helsinn CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Helsinn CINV Existing and Pipeline Drugs Products Offered
10.2.5 Helsinn Recent Development
10.3 Heron Therapeutics
10.3.1 Heron Therapeutics Company Information
10.3.2 Heron Therapeutics Introduction and Business Overview
10.3.3 Heron Therapeutics CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Heron Therapeutics CINV Existing and Pipeline Drugs Products Offered
10.3.5 Heron Therapeutics Recent Development
10.4 Merck
10.4.1 Merck Company Information
10.4.2 Merck Introduction and Business Overview
10.4.3 Merck CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Merck CINV Existing and Pipeline Drugs Products Offered
10.4.5 Merck Recent Development
10.5 Tesaro
10.5.1 Tesaro Company Information
10.5.2 Tesaro Introduction and Business Overview
10.5.3 Tesaro CINV Existing and Pipeline Drugs Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Tesaro CINV Existing and Pipeline Drugs Products Offered
10.5.5 Tesaro Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 CINV Existing and Pipeline Drugs Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 CINV Existing and Pipeline Drugs Industrial Chain Analysis
11.4 CINV Existing and Pipeline Drugs Market Dynamics
11.4.1 CINV Existing and Pipeline Drugs Industry Trends
11.4.2 CINV Existing and Pipeline Drugs Market Drivers
11.4.3 CINV Existing and Pipeline Drugs Market Challenges
11.4.4 CINV Existing and Pipeline Drugs Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 CINV Existing and Pipeline Drugs Distributors
12.3 CINV Existing and Pipeline Drugs Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
